397
Participants
Start Date
December 22, 2020
Primary Completion Date
May 4, 2022
Study Completion Date
August 10, 2022
MM-II dose I
Intra-articular injection
MM-II dose II
Intra-articular injection
MM-II dose III
Intra-articular injection
Placebo
Intra-articular injection
Placebo
Intra-articular injection
Placebo
Intra-articular injection
Sunpharma site no. 01, Herlev
Sunpharma site no. 03, Vejle
Sunpharma site no. 02, Gandrup
Sunpharma site no. 17, Williamsville
SunPharma Site No 24, Columbia
Sunpharma site no. 09, Charleston
Sunpharma site no. 21, Fort Mill
Sunpharma site no. 10, Lady Lake
Sunpharma site no. 04, The Villages
Sunpharma site no. 13, Maitland
Sunpharma site no. 22, Miami
Sunpharma Site no 27, Miami
Sunpharma site no. 12, Miami
SunPharma Site no 23, Miami
Sunpharma site no. 05, Sunrise
Sunpharma site no. 08, Lake Worth
Sunpharma site no. 20, Birmingham
Sunpharma site no. 18, Flossmoor
Sunpharma site no. 07, Hazelwood
Sunpharma site no. 19, Edmond
Sunpharma site no. 11, Tempe
Sunpharma site no. 26, San Diego
Sunpharma site no. 25, Riverside
Sunpharma site no. 06, Stamford
Sunpharma site no. 14, Hong Kong
Collaborators (1)
Moebius Medical Ltd.
INDUSTRY
Nordic Bioscience Clinical Development (NBCD)
UNKNOWN
Sun Pharmaceutical Industries Limited
INDUSTRY